Neoadjuvant FOLFIRINOX versus neoadjuvant chemoradiotherapy and adjuvant chemotherapy for (borderline) resectable pancreatic cancer: Update on the PREOPANC-2 study

Published on Jan 1, 2020in Hpb3.647
· DOI :10.1016/J.HPB.2020.04.191
Quisette P Janssen4
Estimated H-index: 4
,
Marjolein Y.V. Homs17
Estimated H-index: 17
+ 3 AuthorsB. Groot Koerkamp4
Estimated H-index: 4
Source
Abstract
References0
Newest
Cited By2
Newest
#1Giampaolo PerriH-Index: 8
Last. Roberto SalviaH-Index: 57
view all 4 authors...
Background null Pancreatic cancer represents a systemic disease, and its treatment ideally includes the administration of systemic therapy regardless of its anatomical stage. null Methods null In this brief narrative review, the most recent literature will be highlighted, together with updates, new perspectives on the topic, and the authors own personal view. null Results null While preoperative therapy has recently become the new standard for borderline resectable stages, adjuvant therapy after...
Source
#1Kjetil Søreide (University of Bergen)H-Index: 64
Pancreatic cancer has a dismal prognosis. Resection is the best option for cure, supported by multimodal therapy to treat the systemic disease. While adjuvant therapy has become standard in those who are fit and who can tolerate the given regimen, the concept of perioperative (neoadjuvant) therapy is building momentum. The concepts of "borderline" and "locally advanced" have changed the previous dichotomized "resectable/non-resectable" into subcategories for which new algorithms have emerged, wi...
Source
#1Deesje Doppenberg (UvA: University of Amsterdam)H-Index: 1
#2E. van Veldhuisen (UvA: University of Amsterdam)H-Index: 1
Last. Marc G. Besselink (UvA: University of Amsterdam)H-Index: 88
view all 6 authors...
Achieving an R0-resection is a prerequisite for long-term survival in pancreatic cancer. Preoperative therapy may downstage locally advanced and borderline pancreatic cancer and thereby increase the chance of an R0 resection. Promising results of this approach have been reported, with survival rates of 30–34 months following chemotherapy and subsequent resection. Recently, two randomized trials in patients with borderline resectable pancreatic cancer have reported promising outcomes of preoperat...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.